vs

Side-by-side financial comparison of MEDIFAST INC (MED) and Solo Brands, Inc. (SBDS). Click either name above to swap in a different company.

Solo Brands, Inc. is the larger business by last-quarter revenue ($94.0M vs $75.1M, roughly 1.3× MEDIFAST INC). On growth, Solo Brands, Inc. posted the faster year-over-year revenue change (-34.5% vs -36.9%). Over the past eight quarters, Solo Brands, Inc.'s revenue compounded faster (5.0% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

Conagra Brands, Inc. is an American consumer packaged goods holding company that makes and sells products under various brand names that are available in supermarkets, restaurants, and food service establishments. Based on its 2021 revenue, the company ranked 331st on the 2022 Fortune 500. Headquartered in Chicago, Illinois, Conagra was founded in Nebraska in 1919 and was originally called Nebraska Consolidated Mills.

MED vs SBDS — Head-to-Head

Bigger by revenue
SBDS
SBDS
1.3× larger
SBDS
$94.0M
$75.1M
MED
Growing faster (revenue YoY)
SBDS
SBDS
+2.4% gap
SBDS
-34.5%
-36.9%
MED
Faster 2-yr revenue CAGR
SBDS
SBDS
Annualised
SBDS
5.0%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MED
MED
SBDS
SBDS
Revenue
$75.1M
$94.0M
Net Profit
$-83.2M
Gross Margin
69.4%
60.6%
Operating Margin
-10.4%
-81.7%
Net Margin
-88.4%
Revenue YoY
-36.9%
-34.5%
Net Profit YoY
-42.9%
EPS (diluted)
$-1.64
$-45.73

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
SBDS
SBDS
Q4 25
$75.1M
$94.0M
Q3 25
$89.4M
$53.0M
Q2 25
$105.6M
$92.3M
Q1 25
$115.7M
$77.3M
Q4 24
$119.0M
$143.5M
Q3 24
$140.2M
$94.1M
Q2 24
$168.6M
$131.6M
Q1 24
$174.7M
$85.3M
Net Profit
MED
MED
SBDS
SBDS
Q4 25
$-83.2M
Q3 25
$-2.3M
$-22.9M
Q2 25
$2.5M
$-20.8M
Q1 25
$-772.0K
$-18.6M
Q4 24
$-58.2M
Q3 24
$1.1M
$-111.5M
Q2 24
$-8.2M
$-4.0M
Q1 24
$8.3M
$-6.5M
Gross Margin
MED
MED
SBDS
SBDS
Q4 25
69.4%
60.6%
Q3 25
69.5%
60.0%
Q2 25
72.6%
61.3%
Q1 25
72.8%
55.2%
Q4 24
74.1%
61.1%
Q3 24
75.4%
41.8%
Q2 24
73.2%
62.8%
Q1 24
72.8%
59.2%
Operating Margin
MED
MED
SBDS
SBDS
Q4 25
-10.4%
-81.7%
Q3 25
-4.6%
-30.5%
Q2 25
-1.0%
-10.7%
Q1 25
-1.1%
-13.8%
Q4 24
0.6%
-38.5%
Q3 24
1.5%
-122.5%
Q2 24
-4.7%
1.7%
Q1 24
4.5%
-7.4%
Net Margin
MED
MED
SBDS
SBDS
Q4 25
-88.4%
Q3 25
-2.5%
-43.2%
Q2 25
2.3%
-22.5%
Q1 25
-0.7%
-24.0%
Q4 24
-40.6%
Q3 24
0.8%
-118.4%
Q2 24
-4.8%
-3.1%
Q1 24
4.8%
-7.6%
EPS (diluted)
MED
MED
SBDS
SBDS
Q4 25
$-1.64
$-45.73
Q3 25
$-0.21
$-9.22
Q2 25
$0.22
$-8.93
Q1 25
$-0.07
$-0.21
Q4 24
$0.08
$-27.74
Q3 24
$0.10
$-47.72
Q2 24
$-0.75
$-2.14
Q1 24
$0.76
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
SBDS
SBDS
Cash + ST InvestmentsLiquidity on hand
$167.3M
$20.0M
Total DebtLower is stronger
$242.1M
Stockholders' EquityBook value
$198.9M
$46.0M
Total Assets
$248.0M
$360.3M
Debt / EquityLower = less leverage
5.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
SBDS
SBDS
Q4 25
$167.3M
$20.0M
Q3 25
$173.5M
$16.3M
Q2 25
$162.7M
$18.1M
Q1 25
$164.6M
$206.4M
Q4 24
$162.3M
$12.0M
Q3 24
$170.0M
$12.5M
Q2 24
$163.5M
$20.1M
Q1 24
$156.4M
$15.4M
Total Debt
MED
MED
SBDS
SBDS
Q4 25
$242.1M
Q3 25
$235.2M
Q2 25
$238.4M
Q1 25
$427.9M
Q4 24
$150.7M
Q3 24
$161.1M
Q2 24
$162.2M
Q1 24
$170.2M
Stockholders' Equity
MED
MED
SBDS
SBDS
Q4 25
$198.9M
$46.0M
Q3 25
$214.7M
$99.1M
Q2 25
$216.0M
$113.2M
Q1 25
$211.0M
$121.7M
Q4 24
$210.1M
$133.7M
Q3 24
$207.3M
$168.0M
Q2 24
$205.3M
$236.7M
Q1 24
$211.0M
$238.5M
Total Assets
MED
MED
SBDS
SBDS
Q4 25
$248.0M
$360.3M
Q3 25
$268.2M
$431.0M
Q2 25
$269.3M
$459.7M
Q1 25
$280.0M
$692.4M
Q4 24
$284.2M
$495.1M
Q3 24
$291.2M
$553.2M
Q2 24
$293.5M
$642.0M
Q1 24
$302.8M
$648.3M
Debt / Equity
MED
MED
SBDS
SBDS
Q4 25
5.26×
Q3 25
2.37×
Q2 25
2.11×
Q1 25
3.52×
Q4 24
1.13×
Q3 24
0.96×
Q2 24
0.69×
Q1 24
0.71×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
SBDS
SBDS
Operating Cash FlowLast quarter
$-5.3M
$6.4M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
SBDS
SBDS
Q4 25
$-5.3M
$6.4M
Q3 25
$12.1M
$11.2M
Q2 25
$-3.4M
$10.9M
Q1 25
$3.4M
$-75.2M
Q4 24
$-4.9M
$13.0M
Q3 24
$9.1M
$378.0K
Q2 24
$13.1M
$15.7M
Q1 24
$7.3M
$-18.5M
Free Cash Flow
MED
MED
SBDS
SBDS
Q4 25
$-6.6M
Q3 25
$10.8M
Q2 25
$-4.8M
Q1 25
$1.9M
$-78.4M
Q4 24
$-7.2M
$9.0M
Q3 24
$7.7M
$-5.9M
Q2 24
$11.1M
$12.8M
Q1 24
$5.4M
$-20.9M
FCF Margin
MED
MED
SBDS
SBDS
Q4 25
-8.8%
Q3 25
12.0%
Q2 25
-4.5%
Q1 25
1.6%
-101.5%
Q4 24
-6.1%
6.3%
Q3 24
5.5%
-6.3%
Q2 24
6.6%
9.8%
Q1 24
3.1%
-24.5%
Capex Intensity
MED
MED
SBDS
SBDS
Q4 25
1.8%
Q3 25
1.5%
Q2 25
1.3%
Q1 25
1.3%
4.2%
Q4 24
1.9%
2.8%
Q3 24
1.0%
6.7%
Q2 24
1.1%
2.2%
Q1 24
1.1%
2.8%
Cash Conversion
MED
MED
SBDS
SBDS
Q4 25
Q3 25
Q2 25
-1.36×
Q1 25
Q4 24
Q3 24
8.04×
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MED
MED

Segment breakdown not available.

SBDS
SBDS

Sales Channel Directly To Consumer$65.4M70%
Sales Channel Through Intermediary$28.6M30%

Related Comparisons